2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
D

2020 ASCO Update on Waldenström Macroglobulinemia: Zanubrutinib vs. Ibrutinib - Which BTKi Option is Better?

By 2020 ASCO Virtual Direct™ Highlights FEATURING David Maloney
By 2020 ASCO Virtual Direct™ Highlights FEATURING David Maloney
0 views
August 18, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira
Hematologic Oncology
09:23
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: Pembro vs. Brentuximab Vedotin…

Feat. D. Maloney
08:34
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Waldenström Macroglobulinemia: Zanubrutinib vs. …

Feat. D. Maloney
07:09
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on DLBCL: Venetoclax + Dose-Adjusted R-EPOCH - Did …

Feat. D. Maloney
10:30
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on FL: Is CAR-T Axi-Cel Therapy a Promising Therape…

Feat. D. Maloney